Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update

Benitec Biopharma Inc. (NASDAQ:BNTC) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 62,000 shares, a decrease of 6.8% from the August 15th total of 66,500 shares. Based on an average trading volume of 29,200 shares, the days-to-cover ratio is currently 2.1 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Piper Sandler assumed coverage on Benitec Biopharma in a report on Thursday, June 13th. They set an “overweight” rating and a $30.00 price objective for the company. Leerink Partnrs upgraded Benitec Biopharma to a “strong-buy” rating in a research note on Monday, July 22nd. Leerink Partners initiated coverage on Benitec Biopharma in a report on Monday, July 22nd. They issued an “outperform” rating and a $13.00 price objective on the stock. Finally, Guggenheim began coverage on Benitec Biopharma in a report on Thursday, September 12th. They set a “buy” rating and a $17.00 target price for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $19.00.

Benitec Biopharma Trading Down 0.5 %

Shares of BNTC stock opened at $8.36 on Thursday. The stock has a market cap of $78.32 million, a P/E ratio of -4.86 and a beta of 0.90. Benitec Biopharma has a 1 year low of $2.69 and a 1 year high of $10.88. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $8.98 and a 200 day simple moving average of $7.70.

Institutional Trading of Benitec Biopharma

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its position in shares of Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,884 shares during the period. Simplify Asset Management Inc. acquired a new stake in Benitec Biopharma during the second quarter worth about $358,000. Janus Henderson Group PLC increased its holdings in Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after buying an additional 64,092 shares during the period. Finally, Nantahala Capital Management LLC acquired a new position in shares of Benitec Biopharma in the 2nd quarter valued at approximately $5,881,000. 52.19% of the stock is currently owned by institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.